Gene Therapy for Male Erectile Dysfunction

Arnold Melman

Research output: Contribution to journalReview article

9 Scopus citations

Abstract

The potential clinical advantages of a gene transfer therapy-based approach to treatment of genitourinary smooth muscle-based disorders are several: potential single therapy for restoration of normal bladder or erectile function; eliminating the need for daily medication; use in combination with other therapies to reduce dose requirements and side effects; and development of mechanism-based, patient-specific treatment approaches. With the safe administration of hMax-K to men with erectile dysfunction in the first human phase 1 trial and the initiation of the phase 1 trial of hMaxi-K for patients who have detrusor overactivity, we have entered an exciting new era in the development of safe enduring therapies for genitourinary disorders.

Original languageEnglish (US)
Pages (from-to)619-630
Number of pages12
JournalUrologic Clinics of North America
Volume34
Issue number4
DOIs
Publication statusPublished - Nov 1 2007

    Fingerprint

ASJC Scopus subject areas

  • Urology

Cite this